316 related articles for article (PubMed ID: 31819169)
1. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway.
Zhou Q; Huang T; Jiang Z; Ge C; Chen X; Zhang L; Zhao F; Zhu M; Chen T; Cui Y; Li H; Yao M; Li J; Tian H
Oncogene; 2020 Mar; 39(10):2140-2155. PubMed ID: 31819169
[TBL] [Abstract][Full Text] [Related]
2. PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
Hu W; Zheng S; Guo H; Dai B; Ni J; Shi Y; Bian H; Li L; Shen Y; Wu M; Tian Z; Liu G; Hossain MA; Yang H; Wang D; Zhang Q; Yu J; Birnbaumer L; Feng J; Yu D; Yang Y
Hepatology; 2021 Feb; 73(2):674-691. PubMed ID: 32335942
[TBL] [Abstract][Full Text] [Related]
3. PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.
Su Y; Meng L; Ge C; Liu Y; Zhang C; Yang Y; Tian W; Tian H
J Exp Clin Cancer Res; 2024 May; 43(1):142. PubMed ID: 38745188
[TBL] [Abstract][Full Text] [Related]
4. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
[TBL] [Abstract][Full Text] [Related]
5. Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway.
Ding D; Huang H; Jiang W; Yu W; Zhu H; Liu J; Saiyin H; Wu J; Huang H; Jiang S; Yu L
Oncogene; 2017 Nov; 36(48):6691-6700. PubMed ID: 28745317
[TBL] [Abstract][Full Text] [Related]
6. Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC.
Liu Y; Zhang X; Yang B; Zhuang H; Guo H; Wei W; Li Y; Chen R; Li Y; Zhang N
Cancer Res; 2018 May; 78(9):2219-2232. PubMed ID: 29330146
[TBL] [Abstract][Full Text] [Related]
7. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
9. NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.
Li KS; Zhu XD; Liu HD; Zhang SZ; Li XL; Xiao N; Liu XF; Xu B; Lei M; Zhang YY; Shi WK; Cao MQ; Xu YF; Tang ZY; Sun HC
Cell Death Dis; 2020 May; 11(5):335. PubMed ID: 32382041
[TBL] [Abstract][Full Text] [Related]
10. FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter.
Lin Z; Huang W; He Q; Li D; Wang Z; Feng Y; Liu D; Zhang T; Wang Y; Xie M; Ji X; Sun M; Tian D; Xia L
J Exp Clin Cancer Res; 2021 Feb; 40(1):50. PubMed ID: 33522955
[TBL] [Abstract][Full Text] [Related]
11. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway.
Liu J; Zhao SY; Jiang Q; Qu Y; Huang X; Du J; Sun W; Ye Q
Int J Biol Sci; 2020; 16(11):1989-2000. PubMed ID: 32398965
[TBL] [Abstract][Full Text] [Related]
13. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
14. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
15. ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma.
Wang Y; Zhang Y; Mi J; Jiang C; Wang Q; Li X; Zhao M; Geng Z; Song X; Li J; Zuo L; Ge S; Zhang Z; Wen H; Wang Z; Su F
Oncogene; 2022 Jul; 41(29):3680-3693. PubMed ID: 35725908
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
17. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
18. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
[TBL] [Abstract][Full Text] [Related]
19. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
Xu Y; Xu H; Li M; Wu H; Guo Y; Chen J; Shan J; Chen X; Shen J; Ma Q; Liu J; Wang M; Zhao W; Hong J; Qi Y; Yao C; Zhang Q; Yang Z; Qian C; Li J
Cancer Lett; 2019 Jul; 454():78-89. PubMed ID: 30980868
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
